论文部分内容阅读
目的探讨含铋剂四联7d疗法一线治疗幽门螺杆菌感染的临床疗效。方法 120例既往未接受过根除治疗的Hp感染患者,随机分配至三联组和四联组,三联组给予兰索拉唑30mg+阿莫西林1.0g+克拉霉素250mg,(2次/d)治疗7d,四联组给予兰索拉唑30mg+阿莫西林1.0g+克拉霉素250mg+胶体果胶铋150mg,(2次/d),治疗7d。疗程结束4周后行13c-尿素呼气试验检查,结果阴性者判断为Hp根除,同时观察治疗过程中症状缓解率和不良反应。结果四联组Hp的根除率均明显高于三联组,差异有统计学意义(P<0.05)。两组症状缓解率和不良反应发生率相似,差异无统计学意义(P>0.05)。结论含铋剂四联7d疗法根除幽门螺杆菌初治疗效高于标准三联7d疗法。
Objective To investigate the clinical efficacy of bismuth-containing quadruple 7d therapy in the first-line treatment of Helicobacter pylori infection. Methods One hundred and twenty patients with Hp infection who had not been previously treated for eradication were randomly assigned to triple and quadruple cohorts. Lansoprazole 30 mg plus amoxicillin 1.0 mg + clarithromycin 250 mg and clarithromycin 250 mg twice daily for 3 days , Four groups were given lansoprazole 30mg + amoxicillin 1.0g + clarithromycin 250mg + colloidal pectin bismuth 150mg, (2 times / d), treatment 7d. 4 weeks after the end of the course of examination 13c-urea breath test, the results were negative for the determination of Hp eradication, while observing the course of treatment, symptoms and adverse reactions. Results The eradication rate of Hp in the quadruple group was significantly higher than that in the triple group (P <0.05). The two groups of symptoms and adverse reactions were similar, the difference was not statistically significant (P> 0.05). Conclusions The initial treatment of Helicobacter pylori eradication with bismuth-containing quadruple 7-day therapy is higher than the standard triple 7-day therapy.